Plain-English translation of NCT07871071 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the Cognixion ONE, a brain-computer interface communication device designed to help people with ALS (amyotrophic lateral sclerosis) communicate when their speech becomes impaired. The device uses brain signals captured by sensors worn on the scalp, combined with either augmented-reality glasses or a regular screen, to let you select words and have a conversation. Researchers want to see how well this new technology works compared to eye-tracking communication devices you may already be using.
As ALS progresses, many people lose the ability to speak but retain full mental clarity. While eye-tracking communication devices help some people, they don't work for everyone—especially as the disease advances and eye control becomes difficult. This trial tests whether a brain-based communication system could offer another option when other methods stop working.
You likely qualify if…
You likely don't qualify if…
You will visit your home three to five times per week for about one hour per session over 12 weeks, with a trained Cognixion staff member and your caregiver present. During these sessions, you'll use three different communication methods—your current eye-tracking device, the new brain-computer interface with augmented-reality glasses or a regular screen—to complete communication tasks and have conversations. The research team will monitor your disease progression every four weeks with standard assessments, and you'll have at least one visit per month in addition to weekly remote check-ins.
AI-generated summary from trial data · Oct 28, 2026 · Not medical advice
United States